Atelerix Life Sciences is a Delaware C corporation headquartered in Charlottesville, Virginia, developing a family of novel pharmaceutical small molecules targeted at the opioid crisis. A platform of novel drugs called Active Thiol-Based Compounds (ATBCs) can prevent or reverse opioid-induced side effects:
- These drugs target novel molecular pathways – modulating the signaling downstream from activated opioid receptors.
- NIH-supported discovery and pre-clinical development have validated the concept, with compelling data supporting a robust pipeline of novel proprietary lead compounds.
- These new drugs are now being developed for the clinic to treat opioid-induced side effects